U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793332) titled 'BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC' on Dec. 28, 2024.
Brief Summary: This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab govitecan) treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or the investigator deems it necessary to discontinue the medication, and to collect data on the drug's efficacy and safety.
Study Start Date: Dec. 17, 2024
Study Type: INTERVENTIONAL
Condition:...